PhaseBio Pharmaceuticals (PHAS) Sets New 52-Week High at $6.00

Share on StockTwits

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $6.00 and last traded at $5.47, with a volume of 425 shares trading hands. The stock had previously closed at $5.36.

In other PhaseBio Pharmaceuticals news, major shareholder Venture Advisors Iii Hatteras acquired 300,000 shares of the company’s stock in a transaction that occurred on Monday, October 22nd. The stock was bought at an average price of $5.00 per share, with a total value of $1,500,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Linda Tufts acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 22nd. The shares were acquired at an average cost of $5.00 per share, with a total value of $100,000.00. The disclosure for this purchase can be found here.

About PhaseBio Pharmaceuticals (NASDAQ:PHAS)

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply